NTRK2 and early-onset autosomal dominant Alzheimer disease: Chronic oral administration of R13 activates TrkB signaling and suppresses the activity and expression of AEP, which has been proven to possess functions that inhibit bone loss and delay the progression of Alzheimer's disease in our previous studies [17, 18, 35].